Abbott Laboratories (ABT) : Fort Washington Investment Advisors Inc Oh reduced its stake in Abbott Laboratories by 7.16% during the most recent quarter end. The investment management company now holds a total of 2,307,930 shares of Abbott Laboratories which is valued at $86.8 Million after selling 178,077 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on May 13, 2016.Abbott Laboratories makes up approximately 1.70% of Fort Washington Investment Advisors Inc Oh’s portfolio.
Other Hedge Funds, Including , Shelton Capital Management reduced its stake in ABT by selling 26,263 shares or 15.67% in the most recent quarter. The Hedge Fund company now holds 141,347 shares of ABT which is valued at $5.3 Million. Abbott Laboratories makes up approx 0.50% of Shelton Capital Management’s portfolio.Shufro Rose Co boosted its stake in ABT in the latest quarter, The investment management firm added 1,600 additional shares and now holds a total of 9,400 shares of Abbott Laboratories which is valued at $353,440. Abbott Laboratories makes up approx 0.04% of Shufro Rose Co’s portfolio.Focused Wealth Management Inc reduced its stake in ABT by selling 95 shares or 4.61% in the most recent quarter. The Hedge Fund company now holds 1,964 shares of ABT which is valued at $73,846. Abbott Laboratories makes up approx 0.04% of Focused Wealth Management Inc’s portfolio.Smithfield Trust Co boosted its stake in ABT in the latest quarter, The investment management firm added 600 additional shares and now holds a total of 10,312 shares of Abbott Laboratories which is valued at $391,547. Abbott Laboratories makes up approx 0.08% of Smithfield Trust Co’s portfolio. Sabal Trust Co sold out all of its stake in ABT during the most recent quarter. The investment firm sold 8,899 shares of ABT which is valued $337,895.
Abbott Laboratories opened for trading at $38.06 and hit $38.77 on the upside on Wednesday, eventually ending the session at $38.68, with a gain of 1.84% or 0.7 points. The heightened volatility saw the trading volume jump to 1,61,41,174 shares. Company has a market cap of $56,827 M.
On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.